1170PAnalysis of POLE mutation and tumor mutational burden (TMB) across 80,853 tumors: Implications for immune checkpoint inhibitors (ICPIs)
暂无分享,去创建一个
V. Miller | D. Fabrizio | M. Fakih | Siraj M. Ali | S. Ramkissoon | J. Elvin | P. Stephens | A. Schrock | Yuting He | S. Klempner | Jon H. Chung | M. Resnick | J. Ross